GlassScriptPhysician profile
Sneha Patel
NPI 1669676136
$2,837.06
in general payments reported to CMS, 2019-2025
28 companies · $256 in 2025
The $256 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $628 · 2020: $400 · 2021: $457 · 2022: $339 · 2023: $496 · 2024: $261 · 2025: $256.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $934 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $933.80 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $360.72 | 2019-2024 | Lifevest |
| Amgen INC. | $353.01 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $347.24 | 2019-2025 | Farxiga |
| Sanofi-Aventis U.S. LLC | $295.98 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $223.19 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $154.49 | 2019-2021 | |
| Janssen Biotech, INC. | $132.62 | 2023 | Tremfya, Simponi, Simponi Aria |
| Merck Sharp & Dohme LLC | $127.49 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $110.75 | 2019-2025 | Camzyos |
| Mallinckrodt Hospital Products INC. | $99.04 | 2023 | Acthar |
| Conmed Corporation | $98.08 | 2025 | Conmed Biliary |
| Kowa Pharmaceuticals America, INC. | $88.82 | 2019-2021 | |
| Pfizer INC. | $60.00 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.52 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $45.11 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bracco Diagnostics INC. | $30.72 | 2025 | |
| Arbor Pharmaceuticals, INC. | $29.29 | 2019-2021 | |
| Stryker Corporation | $25.87 | 2025 | Na, Smartlock |
| Abbott Laboratories | $25.72 | 2021 | |
| Chiesi USA, INC. | $25.37 | 2024 | Cleviprex, Kengreal |
| Boston Scientific Corporation | $23.53 | 2024 | Watchman Flx |
| Edwards Lifesciences Corporation | $22.65 | 2019-2020 | |
| Bardy Diagnostics, INC. | $20.00 | 2019 | |
| Esperion Therapeutics, INC. | $19.65 | 2025 | Nexletol |
| Kiniksa Pharmaceuticals, LTD. | $17.79 | 2021 | |
| Medtronic USA, INC. | $16.02 | 2019 | |
| Amarin Pharma, INC. | $14.90 | 2022 | |
| Aurinia Pharma U.S., INC. | $13.49 | 2024 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sneha Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.